secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001567264-25-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics reports 2024 net loss of $16.3M; cash $2.6M; trial enrollment ongoing
--------------------------------------------------------------------------------

- Net loss of $16.3M for FY2024 vs $10.5M in 2023; R&D expenses rose to $10.5M from $4.8M.
- Cash and cash equivalents total $2.6M as of December 31, 2024.
- INVINCIBLE-3 (Phase 3 sarcoma) has 32 sites contracted, 25 patients screened; enrollment expected by first half 2026.
- INVINCIBLE-4 (Phase 2 TNBC) has 8 Swiss sites activated, several patients treated; enrollment expected end Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000011/0001567264-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000011/intensity-20250313.htm
  HTML page:      https://secwatch.observer/filing/0001567264-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer